7 completed. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Bronchial Spasm: new trials by email Literature Review of Bronchial Spasm trials Research Report on Bronchial Spasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial Ketamine, Fentanyl - Critical Illness, Asthma | Phase 2 / Phase 3 | Completed | Hospital Nossa Senhora da Conceicao | 45 | 2015-06-04 | 2024-05-21 |
| Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol - Asthma, Bronchospasm | Phase 1 / Phase 2 | Completed | Amphastar Pharmaceuticals, Inc. | 23 | 2010-08-01 | 2017-07-25 |
| Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006 A006, Placebo DPI, Proventil-HFA - Asthma, Bronchospasm | Phase 2 | Completed | Amphastar Pharmaceuticals, Inc. | 27 | 2010-07-01 | 2017-07-02 |
| Dose-Ranging Study of A006 DPI, in Adult Asthma Patients albuterol inhalation powder, Placebo, albuterol inhalation aerosol - Asthma, Bronchospasm | Phase 2 | Completed | Amphastar Pharmaceuticals, Inc. | 26 | 2010-07-01 | 2017-04-19 |
| A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis Epinephrine, Omalizumab (Xolair), Placebos - Anaphylaxis, Hypotension | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 16 | 2009-04-27 | 2019-07-01 |
| Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma senicapoc, Placebo - Exercise Induced Asthma | Phase 2 | Completed | Icagen | 69 | 2009-03-01 | 2011-07-14 |
| Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma AVE2635A - Asthma | Phase 2 | Completed | Sanofi | 1145 | 2005-03-01 | 2009-04-08 |
Asthma (5) · Pulmonary Disease, Chronic Obstructive (2) · Anaphylaxis (1) · Angioedema (1) · Asthma, Exercise-Induced (1) · Critical Illness (1) · Dyspnea (1) · Hypersensitivity (1) · Hypotension (1) · Inflammation (1) · Respiratory Sounds (1)
Bronchial Diseases (7) · Hypersensitivity, Immediate (7) · Immune System Diseases (7) · Respiratory Tract Diseases (7) · Hypersensitivity (6) · Respiratory Hypersensitivity (6) · Lung Diseases (5) · Lung Diseases, Obstructive (5) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Disease Attributes (3) · Chronic Disease (2) · Asthma (1) · Cardiovascular Diseases (1) · Exercise-Induced Allergies (1)
Albuterol (2) · Epinephrine (2) · Fentanyl (1) · Inhalation (1) · Ketamine (1) · OIC-A006 (1) · Omalizumab (1) · senicapoc (1)
Amphastar Pharmaceuticals, Inc. (3) · Hospital Nossa Senhora da Conceicao (1) · Icagen (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Sanofi (1)
United States (6) · Brazil (1)
Jonathon Stocker, Ph.D. (1) · Melody C Carter, M.D. (1)